Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Treating Patients with PNH and AA

Anita Hill • 13 Jun 2019
EHA 2019
Anemias Aplastic Anemia Non-Malignant Paroxysmal Nocturnal Hemoglobinuria Eculizumab

Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, Leeds Teaching Hospital NHS Trust, Leeds, UK, discusses a paper that investigated patients undergoing both concomitant therapy for their aplastic anemia with immunosuppressive therapy, and eculizumab treatment for paroxysmal nocturnal hemoglobinuria (PNH). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Anita Hill

1:25
Erythropoietin in AHA patients
Anita Hill • 13 Jun 2019
2:05
Anita Hill: highlights from EHA 2019
Anita Hill • 13 Jun 2019
1:40
PNH treatment: ravulizumab vs. eculizumab
Anita Hill • 13 Jun 2019
1:50
SAA treatment and QoL
Anita Hill • 13 Jun 2019

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals